AsclepiX Therapeutics

AsclepiX Therapeutics is a company focused on developing groundbreaking therapies for ocular diseases. Using computational biology methods, they have identified peptides that regulate vascular homeostasis. Their lead candidate, AXT107, targets two validated pathways for retinal vascular diseases and has the potential to provide substantial durability with reduced treatment burden.